Preventing Infectious Diseases Flashcards
Risk Factors for Infectious Disease - Developing Countries
- Underweight
- Unsafe sex
- Unsafe water, sanitation and hygeine
- Indoor smoke from solid fuels
- Zinc deficiency
- Vitamin A deficiency
- Tobacco
Risk Factors for Infectious Disease - Developed Countries
- Tobacco
- Illicit drugs
- Unsafe sex
Foodborne Illness
- Caused by the consumption of food contaminated with organisms or their toxins. • •The ‘big five’ bacteria:
- Salmonella
- Campylobacter
- E coli 0157
- Listeria monocytogenes
- Clostridium perfringens
- Important because they cause a lot of cases of intestinal illness or because they cause severe disease, or both
- Factors that may influence spread of infection from food chain to humans include:
- Intensive farming
- Global distribution
- Mass production
- New microbes
- Antibiotic residues
Hospital Acquired Infections
- Neither present or incubating when patient enters hospital but develop during hospital or are present/incuvating when discharged
- Affects 8% of hospital admissions
- Caused by:
- Breaches in normal body defences:
- Surgery
- Invasive devices
- Underlying illness increasing vulnerability
- Impaired immune response
- Diabetic ulcers
- Exposure to micro-organisms
- Endogenous human flora
- Environmental contamination/colonisation
- Breaches in normal body defences:
Hospital Acquired Infections - Mechanisms of Spread
- Hands and contaminated equipment
- MRSA and Group A Streptococcus
- Faecal/oral spread and contaminated environment
- Viral gastroenteritis and C.difficile
- Airborne/droplet
- Viral gastroenteritis and Group A Streptococcus
Hospital Acquired Infections - Sites
- Urinary tract (23%)
- Minor severity
- Risk factors:
- Urinary catheter use
- Prevention:
- Correct management of catheters
- Lower respiratory tract (23%)
- Severe
- Risk factors:
- Ventilation
- Post-surgery
- NG feeding
- Prevention:
- Physiotherapy
- Tracheostomy care
- NG care
- Bloodstream
- Severe
- Risk factors:
- Intravascular devices - ITU/renal/haematology
- Prevention:
- Correct management of lines
Hospital Acquired Infection - Prevention
- Clean environment
- Clean reusable equipment between use
- Hand washing (staff and patient)
- Source and protective isolation
- Meticulous aseptic technique during invasive procedures
- Meticulous care of invasive devices and prompt removal
- Ward closure during outbreak
- Antimicrobial stewardship
- Surveillance
Hospital Acquired Infection - Surveillance
- Mandatory:
- MRSA
- C. difficile
- Glycopeptide resistant enterococci (GRE)
- E.coli
- Surgical Site infections
- Voluntary:
- Methicillin-sensitive Staphlococcus aureus (MSSA)
- Pseudomonas/Acinetobacter/Stenotrophomonas
Antibiotic Prophlaxis - Surgical
- Peri-operative antibiotics may be given to prevent Surgical Site Infection (SSI)
- Responsible for up to 20% of HAI
- Risk depend on type of surgery and patient:
- Clean vs. dirty surgery
- Proceedure complexity
- Foreign material
- Injury to wound tissues
- Severity of illness
- Host immunocompromise
- Diagnosis based on clinical signs not lab results
Antibiotic Prophlaxis - Surgical - Grading
- Clean:
- Non-traumatic
- No inflammation
- No break in technique
- No breach of respiratory, alimentary or genito-urinary tracts
- No prophylaxis needed (unless metalwork or spinal surgery)
- Clean-contaminated:
- Non-traumatic
- Break in technique or breach of respiratory, alimentary or genito-urinary tracts
- No significant spillage
- One dose of antibiotics
- Contaminated:
- Major break in technique
- Gross spillage from a viscus that may contain non-purulent material
- Dirty traumatic wounds
- Faecal contamination
- De-vitalised viscus
- Pus encountered from any source during surgery
- Antibiotics for 5-7 days
Antibiotic Prophlyaxis - Susceptible Populations
- Infective endocarditis - NICE guidance does not recommend antibiotic prophylaxis solely to prevent IE in at-risk patients undergoing dental and non-dental proceedures
- Prevention of invasive pneumococcal disease post-splenectomy
- Decrease the incidence of urinary tract infections
- Prevention of opportunistic infections post solid organ and bone marrow transplants
Antibiotic Prophylaxis - Eradicating Carriage
- Aim is to prevent secondary cases in contacts of people with serious invasive diseases:
- Meningococcal disease
- H.influenzae type B
- Tuberculosis
- Group A Streptococcus
- Contacts identified through contact tracing by CCDC/HPU
Antibiotic Prophylaxis - Pre/Peri/Post Exposure
- Aim is prevent acquisition and development of an infection in relation to a defined exposure or period of exposure:
- Influenza
- HIV
- Malaria
- Hepatitis B
- Perinatal vertical infections:
- HIV
- Beta-haemolytic Streptococcus B
Treatment As Prevention
- Important in developing countries
- Aim to decrease burden of disease and protect whole population:
- Decreased spread
- Decreased environmental contamination
- Examples:
- TB (respiratory droplet spread, 10% contacts of cases of open TB develop active disease)
- Trachoma (worldwide major preventable cause of blindness caused by Chlamydia trachomatis)
- Gut helminths eg. Ascaris (faeces/soil)
Vaccination
- Vaccines induce active immunity and provide immunological memory
- Enables the immune system to recognise and respond rapidly to exposure to natural infection at a later date ==> prevention or modification of disease course
- Vaccines can be made from:
- Attenuated live organisms
- Inactivated (killed organisms)
- Important antigens:
- Inactivated toxoids
- Surface proteins
- Capsular polysaccharide
Vaccination - Routine Vaccinations: Dead vs Alive
- Live:
- Polio (oral)
- MMR
- BCG
- Yellow fever
- Varicella
- Dead/inactivated/toxoid
- Diptheria
- Tetanus toxoid
- Pertussis
- IPV
- Hib
- MenC
- HPV
- Hepatitis B
- Hepatitis A
- Typhoid
- Influenza
- Pneumococcus
- Rabies
Vaccinations - Polysaccharide and Conjugate Vaccines
- Polysaccharide vaccines are made of extracted and purified forms of the bacterial outer polysaccharide coat
- These do not stimulate the immune system as broadly as protein antigens found in tetanus, diptheria or influenza vaccines
- Protection is not long-lasting
- Response in children and infants is poor
- Scome polysaccharide vaccines eg. Hib and MenC have been enhanced by conjugation -
- This involves attatchment of a carrier protein to a polysaccharide antigen ==> better immune reponse and efficacy including in young children
- These do not stimulate the immune system as broadly as protein antigens found in tetanus, diptheria or influenza vaccines
Vaccination - Pneumococcal Vaccination in the UK
- Pneumococcal Conjugate Vaccine (PCV)
- Given to all children <2 years old as part of childhood routine immunisations
- Original PCV contained polysaccharide from 7 common capsular types
- At time of pre-license study covered 89% of invasive pneumococcal infections in the US
- In 2010 DoH approved newer PCV which protects against 13 capsular types of pneumococcal bacteria
- Pneumococcal Polysaccharide Vaccine (PPV)
- Offered to:
- All adults >65 years of age
- All children and adults aged 2-64 years who are considered to be at risk
- PPV provides protection against 23 types of pneumococcus - accounts for 96% of the types of pneumococcus responsible for serious infection in the UK
- Offered to:
Vaccinations For At Risk Groups

Vaccinations - Successful Programmes
- Successes:
- Measles
- Coverage fell to <80% in 2005
- Measles re-established in 2007
- Mostle attributable to unprotected 10-16 year olds missing vaccination in late 90’s and early 2000s - Due to MMR scare
- Haemophilus influenzae b
- Meningococcal C
- Measles
- Impact still unclear:
- BCG
- Typhoid
Meningococcus B Vaccine - Technical Challenges
- Meningococcus B responsible for 60% of meningococcal disease
- Variable capsule and outer membrane
- Able to mimic human structures
- ==> Technically difficult to develop vaccine
Meningococcus B Vaccine - Bexsero
- Four component protein based vaccine
- Routine programmes with and without catch up investigated
- Incidence of invasive meningococcal disease falling
- Immune response as part of UK schedule not assessed
- Efficacy not established
- Uncertain effects on carriage
- Not cost-effective to routinely vaccinate